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location, salary, race, marital status, full-time/part-time status,
prior comorbidity index, prior medical costs related to BPD,
prior other medical costs, index date, and medical services
related to BPD). Treatment groups were compared over a follow-
up period ranging from 12 to 24 months after the index pre-
scription date. RESULTS: Six hundred ninety-nine patients with
BPD were classiﬁed into the ATYP (n = 25), BOTH (n = 190),
NONE (n = 170), and OTHER (n = 314) treatment groups. The
ATYP group demonstrated the lowest rate of employment ter-
mination (1.5%; 95% CI -3.3%, 6.3%) followed by the BOTH
(5.8%; 95% CI 2.5%, 9.1%), NONE (8.9; 95% CI 4.7%,
13.2%), and OTHER (9.3%; 95% CI 6.1%, 12.5%) groups.
Differences between treatment groups were not signiﬁcant. The
numerical difference between ATYP and OTHER did not reach
signiﬁcance (p = 0.058). CONCLUSIONS: The ATYP group
demonstrated the lowest employment termination rate in the
follow-up period of 12 to 24 months after the index prescription
date. Further research is warranted to examine the inﬂuence of
speciﬁc patient variables and treatment regimens on employment
termination in patients with BPD.
PMH32
ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR
DISORDER: EFFECTS ON TOTAL AND MENTAL HEALTH CARE
COSTS
Hassan M1, Madhavan SS2, Rajagopalan K1, Kalsekar ID3, Islam S2,
Makela EH2, Kavookjian J2, Miller LA2
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 2West
Virginia University, Morgantown, WV, USA, 3Butler University,
Indianapolis, IN, USA
OBJECTIVES: Compare total and mental health-related costs
among patients with bipolar disorder (BPD) initiated on queti-
apine versus other antipsychotics in a state Medicaid system.
Economic evaluations comparing quetiapine with other antipsy-
chotics are lacking in the published literature. METHODS:
Retrospective study using “de-identiﬁed” Medicaid claims data
of patients with BPD. Patients assigned to quetiapine (QTP),
olanzapine (OLZ), risperidone (RIS), or typical antipsychotic
groups based on ﬁrst prescription ﬁlled between January 1, 1999
and December 31, 2001. Total and mental health-related costs
(including study drug charges) from 12 months before until 12
months after treatment initiation were analyzed, controlling for
various confounders including patient demographics, comor-
bidities, and prior health care utilization. Total health care costs
included costs associated with medical and mental conditions.
Mental health-related costs were identiﬁed by claims associated
with a mental health disorder (ICD-9-CM codes
290.XX–316.XX) or CPT codes for psychiatric services
(90801–90899) and psychiatric medications. RESULTS: A total
of 825 patients with BPD were classiﬁed into OLZ (n = 283,
34.30%), RIS (n = 231, 28.00%), QTP (n = 106, 12.85%), and
typical antipsychotic (n = 205, 24.85%) cohorts. Mean (±SD)
total health care costs over the 12-month follow-up period were
US$15,866 ± US$23,164 (OLZ), US$17,539 ± US$17,570 (RIS),
US$13,227 ± US$18,862 (QTP), and US$17,570 ± US$23,842
(typical antipsychotics). Mean mental health-related costs over
the 12-month follow-up period were US$10,203 ± US$17203
(OLZ), US$9475 ± US$14202 (RIS), US$8064 ± US$7368
(QTP), and US$7,368 ± US$11,239 (typical antipsychotics).
Adjustment for confounders using multivariate analysis revealed
no signiﬁcant differences in total and mental health-related costs
between the QTP group and the other atypical antipsychotic
groups (OLZ, RIS). For the typical antipsychotic group, there
was greater total (28.4%) and mental health-related (8.7%) costs
compared with the QTP group. CONCLUSIONS: There were
no signiﬁcant differences in total and mental health-related costs
between atypical antipsychotic groups. However, patients with
BPD treated with QTP incurred lower total and mental 
health-related costs compared with those receiving typical
antipsychotics.
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OBJECTIVE: To describe the demographic and clinical charac-
teristics of Texas Medicaid enrollees prescribed AP therapy.
METHODS: This was a retrospective database analysis using
electronic medical records from 1997 to 2001 for adults receiv-
ing AP monotherapy who were continuously enrolled in Texas
Medicaid for at least 18 months. Patients were stratiﬁed accord-
ing to a hierarchy of mutually exclusive primary mental health
(PMH) categories for which AP therapy was presumed to be 
prescribed. RESULTS: Data were available for 19,430 patients.
The population was mainly female (65.7%), white (55.1%) and
older (mean age 60.3 years (SD: 21.9), with 47.6% ≥65 years).
PMH diagnoses were: schizophrenia 16.5%; bipolar disorder
15.5%; dementia 14.3%; psychosis 8.1%; non-psychotic disor-
der 14.5%; no mental health diagnosis 31.1%; with 32.1% of
patients having more than one mental health diagnosis. The per-
centages of index AP therapy were: ﬁrst-generation agent 29.3%;
clozapine 0.5%; olanzapine 21.6%; quetiapine 6.3%; risperi-
done 42.2%. This differed when stratiﬁed by age (c2 = 416.748,
df = 16, p < 0.001), gender (c2 = 76.901, df = 4, p < 0.001),
race/ethnicity (c2 = 160.710, df = 12, p < 0.001) and PMH diag-
nosis (c2 = 845.046, df = 20, p < 0.001). Risperidone use was
more common in those ≥65 years (48.3%), females (43.5%),
Hispanics (46.7%), and for dementia patients (50.1%). Olanza-
pine was primarily used in patients aged 45–54 years (33.6%);
males (31.6%); blacks (35.4%), and for schizophrenia (36.5%).
The mean daily dose of the second-generation antipsychotics
(SGAs) differed by age (p < 0.001) and treatment indication 
(p < 0.001). Regardless of the SGA, patients aged ≥65 years
received doses 43.4–51.2% lower than patients aged < 65 years.
Regardless of age, doses for schizophrenia were 26–46% higher
than for bipolar disorder and 60–70% higher than for dementia
patients. CONCLUSIONS: AP agents are prescribed for a
diverse range of indications with signiﬁcant differences in AP
dose according to treatment indication and patient age.
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OBJECTIVE: We compared factors associated with antidepres-
sant treatment selection for patients initiating on duloxetine
versus venlafaxine XR, bupropion, and SSRIs. We tested differ-
ences in subgroups with and without depression diagnoses.
METHODS:Claims from ﬁve US managed care health plans were
obtained for adult patients initiating on new prescriptions for
select antidepressants between August 31, 2004 to December 31,
2004. Diagnostic and treatment history were established through
prior claims (12 months before index medication date).
